The clinical research community has long assumed that AI models trained specifically on medical literature would outperform general-purpose models when generating protocols, matching patients to trials, or drafting regulatory documents. Recent evidence tells a more complex story.
Studies show fine-tuned biomedical models often underperform their general-purpose counterparts on diverse tasks, particularly outside their training datasets. Smaller specialized models like OpenBioLLM-8B scored 30% on clinical case challenges while the general Llama-3-8B achieved 64%. Fine-tuning appears to narrow reasoning capacity in exchange for domain knowledge that doesn't transfer well.
For patient-to-trial matching, GPT-4 consistently outperformed fine-tuned alternatives on accuracy, though cost remains a consideration for large-scale deployment. The clearest signal for regulatory document generation comes from combining general models with retrieval-augmented generation (RAG), which grounds outputs in verified source documents. RAG-enhanced systems improved clinical reasoning scores from 40% to 80% and achieved near-perfect regulatory compliance for informed consent forms.
Hallucination remains the critical risk across all model types, with documented rates of 1.47% at the sentence level, but a concerning proportion carry clinical significance. Architecture and verification processes matter more than whether a model was fine-tuned on medical text.